Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 13, 2004. The report primarily details a significant strategic acquisition and updates regarding directors' interests in company shares.
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or margin data for the reporting period. However, it discloses specific financial terms for a major acquisition:
- Acquisition Consideration: EUR 453 million in cash.
- Target Assets: Injectable anti-thrombotic agents Fraxiparine(R) and Arixtra(R), plus a manufacturing facility in Notre-Dame de Bondeville, France.
- Historical Sales of Acquired Assets: Fraxiparine(R) generated EUR 319 million in 2003; Arixtra(R) generated EUR 24 million in 2003.
- Operational Impact: The acquired facility employs approximately 650 people.
Material Changes and Strategic Developments
The primary material change is the agreement to acquire Fraxiparine(R) and Arixtra(R) from Sanofi-Synthelabo. This transaction is conditional upon Sanofi-Synthelabo successfully completing its acquisition of Aventis and obtaining requisite clearances from EU and US competition authorities. GSK will assume responsibility for ongoing Arixtra clinical trials as part of the deal.
Guidance, Risks, and Management Commentary
Management cautions investors that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Specific risks are referenced in the "Risk Factors" section of GSK's 2003 Annual Report on Form 20-F. The filing notes that the acquisition is contingent on regulatory approvals and the completion of a third-party merger (Sanofi-Synthelabo/Aventis).
Directors' Interests
The filing reports two changes in directors' interests:
- April 7, 2004: The GSK Employee Trust transferred 12,516 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe are potential beneficiaries.
- April 8, 2004: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in Ordinary Share ADRs from 18,830,189 to 18,773,604 at an average price of $40.93. Directors Dr. J P Garnier and Dr. T Yamada are potential beneficiaries.
Key Facts for Investor Verification
- Verify the status of regulatory clearances for the Sanofi-Synthelabo acquisition of Aventis, as the GSK deal is conditional on this event.
- Confirm the final closing date and cash settlement of the EUR 453 million acquisition.
- Review the 2003 Form 20-F for detailed risk factors referenced in this filing.
- Monitor the integration of the 650 employees at the French manufacturing facility.